Coffee appears to change how your gut functions
It may be a slightly awkward topic, but many of us know the feeling: that cup of coffee that gets things moving. Research now suggests that regular coffee… read more.
It may be a slightly awkward topic, but many of us know the feeling: that cup of coffee that gets things moving. Research now suggests that regular coffee… read more.
More than half of patients (56%) are comfortable with artificial intelligence (AI) making diagnosis or treatment decisions when their healthcare provider can change or override them, but that… read more.
ArriVent BioPharma, Inc. announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer… read more.
Idorsia Ltd announced that it is advancing a new development program to investigate daridorexant in autism spectrum disorder (ASD). The company is working on a dedicated formulation in… read more.
Priovant Therapeutics has published results from the Phase 2 portion of the BEACON study of oral brepocitinib in adults with cutaneous sarcoidosis (CS) in JAMA Dermatology. Dr Misha… read more.
Nonprofit hospitals in communities with the greatest financial needs offer similar eligibility for free care as hospitals in less disadvantaged communities, according to a new national study from… read more.
When it comes to hormone-disrupting chemicals, people worry most about what they eat and drink and least about what they put on their skin, according to new research… read more.
Johnson & Johnson announced that Study 452, the second pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features in… read more.
Eli Lilly and Company announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea (OSA)… read more.
CRISPR Therapeutics has presented Phase 1b data for CTX310 in patients with severe hypertriglyceridemia (sHTG) in a late-breaking oral presentation at the AHA Scientific Sessions 2026. CTX310 is… read more.
They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted kilos. But while medications such as Ozempic and Wegovy may also improve women’s chances… read more.
An upcoming study of thousands of Americans aims to measure how effectively U.S. Food and Drug Administration-approved medications, including nicotine patches and prescription pills, help people quit smoking… read more.